RETRANSMISSION: Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
RETRANSMISSION: Therma Bright Secures Nationwide U.S. Distribution Partner For Venowave
Nationwide partner launches initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures
全国合作伙伴推出初步Venowave销售计划,以评估医疗保险/医疗补助的报销时间和计费程序。
Post initial program success, distributor commits to acquire remaining inventory that totals up to USD $2.38M in reimbursement value
初步计划取得成功后,经销商承诺收购剩余库存,总计价值238万美元的报销金额。
Toronto, Ontario--(Newsfile Corp. - August 23, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is proud to announce the addition of a new Nationwide U.S. Durable Medical Equipment (DME) distribution partner that has launched an initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures. Post initial program success, distributor commits to acquire remaining inventory that totals up to USD $2.38M in reimbursement value. The new partner's name will be disclosed in future upcoming releases, following initial program success.
多伦多,安大略省--(新闻稿公司-2024年8月23日)- Therma Bright Inc(TSXV: THRM)(OTCQB: TBRIF)(FSE: JNX)(以下简称"Therma"或"公司"),一家在各种尖端专有诊断和医疗器械技术方面进行开发和投资合作的创业公司,自豪地宣布与一家新的全美耐用医疗器械(DME)分销合作伙伴合作,该合作伙伴推出了一项初步Venowave销售计划,以评估医疗保险/医疗补助的报销时间和计费程序。初步计划取得成功后,经销商承诺收购剩余库存,总计价值238万美元的报销金额。合作伙伴的名称将在未来的发布中披露,以说明初步计划的成功。
With strong distribution network interest, Therma Bright expects its current inventory of 2,000 units-representing up to USD $2.38 million in reimbursement value-to be quickly sold with strong demand for additional orders. The device, effective for ten (10) circulatory indications, offers up to USD $1,199 reimbursement, which will significantly contribute to the Company's revenue and pave the way for sustained growth and enhanced marketplace valuation.
在强大的分销网络兴趣下,Therma Bright预计其目前的2,000套库存(代表238万美元的报销价值)将很快销售完毕,对额外订单的需求很旺盛。该设备适用于10个血液循环适应症,可获得1,199美元的报销,这将极大地为公司的营业收入做出贡献,并为持续增长和提高市场估值铺平道路。
The new DME partner's program offers favorable payment terms to Therma Bright which reflects the partner's confidence in Venowave, its market readiness, the robust HCPCS reimbursement set-up and the expected reimbursement timing. According to RXVantage "'Days to Pay' from service average 54 days during the miscellaneous HCPCS code period. But, they quickly 'normalize' to under 30 days after the HCPCS code is issued."
新的耐用医疗器械合作伙伴计划为Therma Bright提供了有利的付款条件,反映出合作伙伴对Venowave的信心,其市场准备,强大的HCPCS报销设置以及预期的报销时间。根据RXVantage的说法"在 HCPCS 代码期间,' Days to Pay' 平均为 54 天。但是,在发放 HCPCS 代码后的 30 天内,他们很快就会'恢复正常'。"
"We are thrilled to welcome our Nationwide distribution partner to our team, and look forward to working with them closely on this program to demonstrate to their medical network the speed of reimbursement, as well as our efficient order and delivery process," shared Rob Fia, CEO of Therma Bright. "We expect the program to be successful, leading to a significant increase in Venowave orders on a monthly basis and accelerating our revenue growth."
"我们很高兴欢迎我们的全国分销伙伴加入我们的团队,并期待与他们密切合作,以展示给他们的医疗网络报销的速度,以及我们高效的订购和交付流程," Therma Bright 的首席执行官 Rob Fia 分享道。"我们预计该计划将取得成功,每月Venowave订单将大幅增加,并加快我们的营业收入增长。"
The Venowave VW5 is a series of compact, battery-operated peristaltic pumps that generate a wave-form motion. When worn below the knee, strapped firmly to the calf, the device results in compression of the calf and consequently an increased upward volumetric displacement of venous and lymph fluid. The 2-pair unit induces improved vascular and lymphatic flow in the lower limbs. Operating with a single rechargeable 1.5 V NiMh AA battery, this FDA-designated Durable Medical Equipment device enables users to receive treatment anywhere while remaining active. The Venowave VW5 assures it can withstand repeated use by successive patients.
Venowave VW5是一系列紧凑型、电池操作的蠕动泵,可以产生波形运动。当佩戴在膝盖下方时,紧紧绑在小腿上,会导致小腿的压缩,从而提高静脉和淋巴液的向上体积位移。 2对装置在下肢诱导改善血管和淋巴流动。使用单个可充电1.5 V NiMh AA电池,这款FDA指定的耐用医疗设备允许用户在保持活跃的同时在任何地方接受治疗。 Venowave VW5保证可经受连续患者的重复使用。
HCPCS Level II code E068 qualifies for reimbursement for ten (10) indications, including:
E068 HCPCS二级代码适用于十(10)个指征,包括:
- Prevention of deep vein thrombosis (DVT)
- Management of the symptoms of post-thrombotic syndrome (PTS)
- Prevention of primary thrombosis
- Treatment of lymphedema
- Diminishing post-operative pain and swelling
- Treatment of leg swelling due to vascular insufficiency
- Treatment of varicose veins
- Treatment of chronic venous insufficiency
- Enhancing blood circulation
- Treatment of intermittent claudication
- 预防深静脉血栓形成(DVT)
- 管理后血栓性综合症(PTS)症状
- 预防原发性血栓形成
- 淋巴水肿的治疗
- 缓解术后疼痛和肿胀
- 治疗由于血管功能不足引起的腿部肿胀
- 静脉曲张的治疗
- 治疗慢性静脉功能不全
- 增强血液循环
- 间歇性跛行的治疗
About Therma Bright Inc.
Therma Bright Inc.简介:Therma Bright是一家开发商和合作伙伴,在各种领先的专有诊断和医疗器械技术方面致力于为消费者和医疗专业人士提供质量卓越,创新的解决方案,以应对当今最重要的医疗和医疗保健挑战。在TSXV:THRM,OTCQB:TBRIF,FSE:JNX上交易。访问:。
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
Therma Bright Inc.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
Rob Fia,首席执行官
rfia@thermabright.com
rfia@thermabright.com
关注我们的Twitter账号
FORWARD-LOOKING STATEMENTS
前瞻性声明
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
TSX Venture Exchange及其监管服务提供商(如TSX Venture Exchange政策中所定义)对本新闻稿的充分性或准确性不承担责任。